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Abstract
Several novel bisbenzylisoquinoline alkaloids (BBIQAs) have recently been isolated from a
Matis tribe arrow poison and shown by two-electrode voltage-clamp to inhibit mouse muscle
nicotinic acetylcholine receptors (nAChR). Here, using radioligand assay with Aplysia cali-
fornica AChBP and radioiodinated α-bungarotoxin ([125I]-αBgt), we show that BBIQA1,
BBIQA2, and d-tubocurarine (d-TC) have similar affinities to nAChR orthosteric site. How-
ever, a competition with [125I]-αBgt for binding to the Torpedo californica muscle-type
nAChR revealed that BBIQAs1, 2, and 3 are less potent (IC50s = 26.3, 8.75, and 17.0 μM)
than d-TC (IC50 = 0.39 μM), while with α7 nAChR in GH4C1 cells, BBIQA1 was less potent
that d-TC (IC50s = 162 μM and 7.77 μM, respectively), but BBIQA2 was similar (IC50 =
5.52 μM). In inhibiting the Ca2+ responses induced by acetylcholine in Neuro2a cells
expressing the mouse adult α1β1εδ nAChR or human α7 nAChR, BBIQAs1 and 2 had simi-
lar potencies to d-TC (IC50s in the range 0.75–3.08 μM). Our data suggest that BBIQA1 and
BBIQA2 can inhibit adult muscle α1β1εδ nAChR by both competitive and noncompetitive
mechanisms. Further experiments on neuronal α3β2, α4β2, and α9α10 nAChRs, expressed
in Xenopus laevis oocytes, showed that similar potencies for BBIQAs1, 2, and d-TC. With
α3β2γ2 GABAAR currents were almost completely inhibited by d-TC at a high (100 μM) con-
centration, but BBIQAs1 and 2 were less potent (only 40–50% inhibition), whereas in com-
petition with Alexa Fluor 546-α-cobratoxin for binding to α1β3γ2 GABAAR in Neuro2a cells,
d-TC and these analogs had comparable affinities. Especially interesting effects of BBI-
QAs1 and 2 in comparison with d-TC were observed for 5-HT3AR: BBIQA1 and BBIQA2
were 5- and 87-fold less potent than d-TC (IC50 = 22.63 nM). Thus, our results reveal that
these BBIQAs differ from d-TC in their potencies towards certain Cys-loop receptors, and
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we suggest that understanding the reasons behind this might be useful for future drug
design.
Introduction
The nicotinic acetylcholine (nAChR), glycine (GlyR), serotonin (5-HT3R), and γ-aminobu-
tyric acid (GABAAR) receptors belong to the Cys-loop family of ligand-gated ion channels
(LGICs) [1–5]. All members of this family have a similar structure: five subunits form a penta-
mer surrounding a selective ion channel; for nAChR and 5-HT3R, the ion channel is perme-
able to cations, while in GABAAR and GlyR it is anion-permeable. Each subunit is composed
of an N-terminal extracellular domain, four transmembrane fragments (M1-M4), and a large
cytoplasmic loop between M3 and M4 fragments. In the N-terminal extracellular domain,
there is a highly conserved 13 amino acid loop tethered at each end by a cysteine disulfide
bridge, hence the name “Cys-loop receptors” [6–8].
Ligands for Cys-loop receptors are very diverse and include both synthetic and natural
compounds. Typically, agonists and competitive antagonists bind to the orthosteric sites
located between two adjacent subunits, whereas allosteric binders target different sites [9–11].
Cys-loop receptors are widely expressed in the central and peripheral nervous systems, where
they mediate fast synaptic neurotransmission, and also in other systems, for example, in
immune and epithelial cells [12–16]. Drugs that act at Cys-loop receptors are used as muscle
relaxants, chronic pain therapeutics, anti-emetics, neurodegenerative and psychiatric thera-
peutics, smoking cessation aids and new compounds are being actively sought [17–20]. Muscle
relaxants and/or neuromuscular blocking agents are widely used in anesthesia, where they act
by interrupting transmission at the neuromuscular junction [21]. The development of clinical
muscle relaxants began with the examination of the arrow poison produced from plant Chon-
dodenron tomentosum by South American Indians [21, 22] and by isolation of d-tubocurarine
(d-TC) [23]. d-TC is an antagonist of the end-plate muscle type nAChRs, which are composed
by two α1, one β1, one δ, and either γ (fetal) or ε (adult) subunits. The orthosteric α/ε (or α/γ)
site binds d-TC with 100-fold higher affinity than the orthosteric α/δ site [24]. In the middle of
the last century, d-TC was a popular choice in surgery, although there were some adverse
effects on blood pressure and the cardiovascular system [22, 25]. Today the compounds used
are much safer, but still so there are some side effects and there is a strong need in understand-
ing the key structural elements important for high selectivity of the muscle relaxants. In partic-
ular, in addition to high selectivity, the perfect relaxant should be characterized by rapid onset
and short or intermediate duration of action [21, 26, 27].
We have recently described an analysis of a poison which the Matis tribe in South America
is using for anointing their arrows [28]. In addition to a number of well-known compounds,
such as magniflorine, lindoldhamine and some others [29, 30], a series of novel bisbenzyltetra-
hydroisoquinoline alkaloids (BBIQAs) (Fig 1) were discovered. Due to their structural similar-
ity with d-TC, it was reasonable to expect from them the inhibition of neuromuscular
transmission. Indeed, it was found that both the crude venom (at a concentration of 1.0 mg/
mL), and individual BBIQAs at the relatively high concentration of 20 μM, efficiently
decreased the amplitudes of ACh-induced currents in mouse muscle nAChR heterologously
expressed in X. laevis oocytes [28].
The aim of the present work was a detailed in vitro comparison of d-TC and BBIQAs activi-
ties on a set of muscle-type and neuronal nAChRs. Previous work has shown that d-TC is able
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to block nAChRs competitively and noncompetitively, depending on the nAChR subtype:
inhibition of neuronal α4β2 nAChR is competitive, while muscle-type and neuronal α3β4
nAChRs are blocked by a mixed mechanism involving binding to both orthosteric and alloste-
ric sites [31]. d-TC binds with a high affinity to acetylcholine-binding protein (AChBP), a
good model for studying agonist and competitive antagonist actions on nAChR [32]. Interest-
ingly, d-TC adopts three different orientations in the AChBP ligand binding sites [33], provid-
ing a possible reason for the wide range of receptors targeted by d-TC: in addition to nAChRs,
d-TC is an effective blocker of 5-HT3R (with IC50 values of 11.4–13 nM and 1.8 μM for mouse
and human 5-HT3AR, respectively [34, 35]), and at higher concentrations (30 μM) it also
inhibits GABAAR [36]. In the current research we compared the effects of d-TC and the novel
BBIQAs on muscle-type and neuronal nAChRs, as well as on 5-HT3AR and GABAAR. Our
data suggest that BBIQAs do not completely mimic the effects of d-TC and thus could help in
the identification of structural motifs responsible for selectivity of distinct compounds, which
is valuable for future drug design.
Fig 1. Chemical structures of d-tubocurarine (d-TC) and bisbenzyltetrahydroisoquinoline alkaloids (BBIQAs).
https://doi.org/10.1371/journal.pone.0210182.g001
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Materials and methods
Materials
The Matis poison (5.29 g) was obtained in Leticia, at the Colombian-Brazilian border, by Dr.
Rainer W. Bussmann. The material was authenticated and deposited at the William L. Brown
Center, Missouri Botanical Garden, in November 2011. Powdered material was maintained at
room temperature (22–25˚C) and protected from light until required for extraction and analy-
sis. T. californica electric organ membranes were a generous gift from Ferdinand Hucho (Free
University of Berlin, Berlin, Germany) and GH4C1 cells–from EliLilly (London, UK). Mouse
neuroblastoma Neuro2a cells were purchased from the Russian collection of cell cultures
(Institute of Cytology, Russian Academy of Sciences, Saint Petersburg, Russia). Mature X. lae-
vis female frogs used in this study were obtained commercially (NASCO, Fort Atkinson WI,
USA) and housed in a facility with 12:12 hours light:dark cycles, 18–20˚C ambient tempera-
ture. Animals were fed twice a week and maintained according to supplier recommendations
(https://www.enasco.com/page/xen_care). This study was carried out in strict accordance with
the World Health Organization’s International Guiding Principles for Biomedical Research
Involving Animals. The protocol was approved by the Institutional Policy on the Use of Labo-
ratory Animals of the Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry RAS (Proto-
col Number: 251/2018 26.02.18). All frog surgery was performed under benzocaine anesthesia,
and all the appropriate actions were taken to minimize discomfort to frogs.
Samples purification
Preparative purification was carried out with a Gilson HPLC system (322 pump with GX 271
liquid handler) equipped with an RP column and 155 UV-Vis detector, set at 210 and 254 nm.
Compounds were eluted with a H2O-MeCN gradient with 0.1% CF3COOH. UPLC-MS analy-
sis was performed using Thermo Finnigan LCQ Deca XP Plus ion trap instrument with
Thermo Accela UPLC system equipped with YMC Triart column (C-18 150 × 2 mm, 1.9 μm).
Detection was achieved by UV-VIS DAD (190–600 nm) and full scan MS (ESI+, 150–2000
au). Crude samples were dissolved in mixture of water/methanol/acetic acid 88:10:2 to a final
concentration of 3 mg/mL, filtered through a 45 μm nylon filter and injected into the LC sys-
tem. Chromatography was carried out using a Phenomenex Luna C18(2) 5 μm 21.2x150 mm
column in a linear gradient from 9 to 55% of acetonitrile in 15 Column Volumes. Fractions of
interest were collected, analyzed by UPLC-MS and lyophilized.
Computer modeling with A. californica AChBP
Docking experiments were performed using Autodock 4.2 and analyzed with MGL Tools 1.5.6
[37] with parameters set as follows: genetic algorithm population size 150, number of evalua-
tions 25000000 and number of runs 100. The structure of A. californica AChBP co-crystallized
with d-TC was used as a receptor (PDB 2XYT) which contains d-TC in three distinct binding
positions [33]. To address the possibility of different binding modes we performed docking of
BBIQA1 and BBIQA2 to all three types of binding sites. Results were clustered and inspected
using MGL Tools 1.5.6 and visualized using UCSF Chimera [38].
Radioligand assay
In competition experiments with [125I]-αBgt, the compounds were pre-incubated 3 h at room
temperature with A. californica AChBP at final concentrations of 140 nM, T. californica elec-
tric organ membranes (final concentration 1.25 nM of toxin-binding sites) or GH4C1 cells
(6.5 μg of total protein with final concentration of 0.4 nM of toxin-binding sites) in 50 μL of
Curare alkaloids inhibit Cys-loop receptors
PLOS ONE | https://doi.org/10.1371/journal.pone.0210182 January 4, 2019 4 / 17
binding buffer (20 mM Tris-HCl buffer, 1 mg/mL of bovine serum albumin, pH 8.0). [125I]-
αBgt was then added to cells or membranes to a final concentration of 0.1–0.2 nM and the
mixtures were incubated for 5 min. Binding was stopped by rapid filtration on GF/C filters
(Whatman, UK) pre-soaked in 0.25% polyethylenimine, unbound radioactivity being removed
from the filters by washing (3×3 mL) with binding buffer. Non-specific binding was deter-
mined in all cases using a 3 h pre-incubation with 30 μM α-cobratoxin (αCtx). The results
were analyzed using OriginPro 2017 (OriginLab Corporation, Northampton, MA, USA) fit-
ting to a dose-response curve with a variable Hill slope using the equation y = A1 + (A2-A1)/(1
+ 10(LOGx0-x)
�p): where A1 and A2 are bottom and top asymptotes, respectively; p–Hill slope;
LOGx0 –log10[IC50, M].
Cell culturing and transfection
Mouse neuroblastoma Neuro2a cells were cultured in Dulbecco’s modified Eagle’s medium
(DMEM, Paneco, Russia) supplemented with 10% FBS (PAA Laboratories, Austria). Cells
were sub-cultured 24 h before transfection and plated at a density of 10,000 cells per well
(black 96-well plate, Corning, USA), followed by lipofectamine (Invitrogen, USA)-mediated
transient co-transfection of human α7 nAChR-pCEP4, fluorescent calcium sensor pCase12--
cyto (Evrogen, Russia) and chaperone Ric3-pCMV6-XL5 or NACHO TMEM35-pCMV6-XL5
plasmid constructs (OriGene, USA). Mouse muscle α1, β1, ε, and δ nAChR-pRBG4 plasmid
constructs were expressed similarly, but without a chaperone, as well as mouse α1, β3, γ2
GABAAR-lab-pCI plasmids.
Calcium imaging
Calcium imaging was performed as described previously [39]. Briefly, cell medium was re-
moved and cells were washed with external buffer containing (in mM) 140 NaCl, 2 CaCl2, 2.8
KCl, 4 MgCl2, 20 HEPES, 10 glucose at pH 7.4. Cells were pre-incubated with d-TC, BBIQA1,
or BBIQA2 for 20 min at room temperature, or with αBgt for 5 min at room temperature. To
potentiate α7 nAChR responses, PNU120596 (10 μM) was added to the pre-incubation solu-
tion. Cells were excited at 485 nm and emitted fluorescence was detected at 535±10 nm, using
a multimodal microplate reader Hidex Sense (Hidex, Turku, Finland). Fluorescence was re-
corded every 2 s for 3 min following agonist addition. Responses were measured as peak inten-
sity minus basal fluorescence level, and are expressed as a percentage of a maximal response to
agonist. Negative controls were run in the presence of 5 μM αCtx. Data files were analyzed
using HidexSence software (Hidex, Turku, Finland) and then the results were analyzed using
OriginPro 2017 (OriginLab Corporation, Northampton, MA, USA) fitting to a dose-response
curve with a variable Hill slope using the equation y = A1 + (A2-A1)/(1 + 10(LOGx0-x)
�p):
A1 and A2 are bottom and top asymptotes, respectively; p–Hill slope; LOGx0 –log10[IC50 or
EC50, M].
Fluorescence assay
Fluorescence assays were performed as previously described [40]. Neuro2a cells transiently
expressing α1β3γ2 GABAAR were washed with the external buffer. Cells were then pre-incu-
bated with 50 μM d-TC, BBIQA1, or BBIQA2 for 15 min at room temperature followed by 20
min incubation with 50 nM Alexa Fluor 546 αCtx conjugate in a final volume of 100 μL. Cells
were then washed 3 times with two-fold excess buffer. Non-specific fluorescence was deter-
mined using 3 μM αCtx. Pictures of 3 independent fields chosen in blind mode in each plate
well were taken using an epifluorescent microscope IX71 (Olympus, Japan) equipped with a
digital CCD camera. Fluorescence intensity was counted using CellX and ImageJ open-source
Curare alkaloids inhibit Cys-loop receptors
PLOS ONE | https://doi.org/10.1371/journal.pone.0210182 January 4, 2019 5 / 17
software. Fluorescence intensity was normalized to the mean integral intensity of the field
incubated in presence of 50 nM Alexa Fluor 546 αCtx conjugate. Each experimental point is
an average of integral intensity independently measured for 12 independent fields.
Electrophysiology
Plasmid pT7TS constructs of human nAChR α3, α9, α10, and β2 subunits were linearized with
Xba I (NEB, USA), and the plasmid pGEMHE construct with the mouse 5-HT3A subunit–with
Nhe I (NEB, USA). Linearized plasmid constructs were subjected to in vitro cRNA transcrip-
tion using the T7 mMessage mMachine transcription kit (AMBION, USA). Stage V-VI X. lae-
vis oocytes were defolliculated with 2 mg/mL collagenase Type I (Life Technologies, USA) at
room temperature (21–24˚C) for 2 h in Ca2+-free Barth’s solution composed of (in mM) 88
NaCl, 1.1 KCl, 2.4 NaHCO3, 0.8 MgSO4, and 15 HEPES-NaOH at pH 7.6. Oocytes were
injected with 9.2 ng of cRNAs of human nAChR α3β2, α9α10 (in a ratio 1:1), or mouse
5-HT3AR, or 2–3 ng of cDNAs of rat α4β2 (in a ratio 1:1, pcDNA3.1 vector), or mouse α3, β2,
and γ2 GABAAR subunits in pCI vector. Oocytes were incubated at 18ºC in regular Barth’s
solution composed of (in mM) 88 NaCl, 1.1 KCl, 2.4 NaHCO3, 0.3 Ca(NO3)2, 0.4 CaCl2, 0.8
MgSO4, and 15 HEPES-NaOH at pH 7.6, supplemented with 40 μg/mL gentamicin and
100 μg/mL ampicillin for 4 days before electrophysiological recordings. Two-electrode voltage
clamp recordings were made using a turbo TEC-03X amplifier (Npi electronic, Germany) and
WinWCP recording software (University of Strathclyde, UK), at a holding potential of -60
mV. Oocytes were briefly washed with Barth’s solution (for human nAChR α3β2, rat nAChR
α4β2, mouse 5-HT3AR, and mouse α3β2γ2 GABAAR) or Ba
2+ Ringer’s solution composed of
(in mM) 115 NaCl, 2.5 KCl, 1.8 BaCl2, 10 HEPES at pH 7.2 (for human α9α10 nAChR) fol-
lowed by 3 applications of agonist. Washout with Barth’s or Ba2+ Ringer’s solution was done
for 5 min between agonist applications. Oocytes were pre-incubated with d-TC, BBIQA1, or
BBIQA2 for 5 min followed by co-application with agonist (3 s). Peak current amplitudes of
agonist-evoked responses were measured before and after pre-incubation of oocytes with d-
TC, BBIQA1, or BBIQA2. The ratio between these two measurements was used to assess the
activity of d-TC, BBIQA1, or BBIQA2 on human nAChR α3β2, α9α10, rat α4β2, mouse
5-HT3AR, and mouse α3β2γ2 GABAAR. The results for 5-HT3AR were analyzed using Origi-
nPro 2017 (OriginLab Corporation, Northampton, MA, USA) fitting to a dose-response curve
with a variable Hill slope using the equation y = A1 + (A2-A1)/(1 + 10(LOGx0-x)
�p): A1 and A2
are bottom and top asymptotes, respectively; p–Hill slope; LOGx0 –log10[IC50, M].
Data and statistical analysis
Data are presented as mean with 95% confidence interval (CI) or mean ± SEM for the indi-
cated number of independent experiments (n). Statistical analysis (One-way ANOVA with
Tukey’s HSD test) was performed using OriginPro 2017 software (OriginLab Corporation,
Northampton, MA, USA). In all the tests, p< 0.05 was taken as significant.
Results
Computer modeling with A. californica AChBP
Molecular docking studies were performed to detect possible activity against nAChRs. It was
not unexpected for BBIQAs to bind to nAChR because they have structures similar to that of
d-TC. However, such intuitive suggestion should be tested with A. californica AChBP, co-crys-
tallized with the d-TC, an excellent nAChR model for this work [33]. Docking results showed
the potential for high affinity binding of BBIQA1 and BBIQA2 at the A. californica AChBP
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binding site (S1 Table). BBIQA1 docking poses differed substantially from the experimentally
observed d-TC orientations, possibly due to greater structure flexibility (S1A Fig), while pre-
dicted BBIQA2 binding poses (S1B Fig) were similar. All docking simulations predicted
BBIQA1 (S1C Fig) and BBIQA2 (S1D Fig) to bind at the classic orthosteric site under loop C
of AChBP.
Samples purification
All experiments were carried out on BBIQAs1-3 after additional HPLC purification and using
individual peaks according to analytical HPLC (S2–S7 Figs). The mass spectra given for each
of these compounds provide further confirmation of their purity and structure.
Radioligand Assay
Radioligand analysis was performed using [125I]-α-bungarotoxin (αBgt) with a specific activity
of 500 Ci/mmol and either A. californica AChBP, membrane-bound nAChRs from the electric
organ of the T. californica ray, or human α7 nAChR in GH4C1 cells as previously described
[41].
BBIQA1 and BBIQA2 demonstrate a little lower ability to compete with [125I]-αBgt for
binding to A. californica AChBP in comparison with d-TC, their IC50 values were 3.80 μM,
7.63 μM, and 2.41 μM, respectively (Fig 2A and Table 1). In case of T. californica nAChR (Fig
2B and Table 1) the lowest affinity was registered for BBIQA1 (IC50 26.3 μM), with slightly
higher values for BBIQA3 (17 μM), and BBIQA2 (8.75 μM). However, even BBIQA2 was
22-fold less potent than d-TC (IC50 0.39 μM). Inhibition of specific [125I]-αBgt binding to α7
nAChR (Fig 2C) revealed that the affinity of BBIQA1 is low (IC50 162 μM), but that of
BBIQA2 is similar to d-TC (IC50 5.52 μM and 7.77 μM, respectively).
Calcium imaging
The next step was the analysis of BBIQAs interactions with mouse adult muscle nAChR
(α1β1εδ) (Fig 3A and 3C) which differs by one subunit (ε) from the T. californica nAChR
(α1β1γδ). This receptor was heterologously expressed in Neuro2a cells and the inhibitory
Fig 2. Inhibition of [125I]-labeled α-bungarotoxin binding. (a) to A. californica AChBP, (b) to nAChR from Torpedo californica electric organ membranes, and (c) to
human α7 nAChR in GH4C1 cells with BBIQA1 (open blue triangles), BBIQA2 (open red squares), BBIQA3 (open green rhombuses), and d-TC (open black circles). Data
are mean ± SEM of two biological replicates with duplicates for each point (the number of technical replicates is 2), i.e. n = 4. IC50 values derived from these data are
shown in Table 1.
https://doi.org/10.1371/journal.pone.0210182.g002
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effects of BBIQAs on the ACh-induced increase in intracellular Ca2+ concentration ([Ca2+]i)
were monitored based on the fluorescence of the co-expressed calcium ion sensor Case12 as
described in [39]. As seen from Fig 3A and Table 1, BBIQA1 and d-TC have virtually identical
IC50 values (0.75 and 0.81 μM, respectively) and BBIQA2 is ~2-fold less potent (1.75 μM).
The same relationship was observed for the human α7 nAChR expressed in Neuro2a cells and
analyzed in the presence of a positive allosteric modulator PNU120596 (Fig 3B). Due to
extremely rapid desensitization rate of α7 nAChR, its kinetics is too fast to be measured using
any conventional calcium imaging techniques [42–45]. Instead, the application of its positive
allosteric modulator PNU120596 significantly decreases α7 nAChR desensitization rate pro-
viding the possibility to monitor as the receptor-mediated intracellular calcium raises [46, 47].
PNU120596 binds to the transmembrane domain of the α7 receptor leading to an increase of
the maximal agonist-elicited response, agonist potency and apparent cooperativity [48–50]. In
general, positive allosteric modulators have little to no effect on equilibrium binding of α7
competitive antagonists, because these modulators bind in a non-competitive manner, away
from the traditional agonist binding site [51]. However, we must be cautious with calcium
imaging data interpretation, as PNU120596 could affect the data on inhibition of α7 nAChR
by BBIQAs due to their complex character of interaction.
The IC50 values for d-TC and BBIQA1 were 2.03 and 1.70 μM, respectively, while for
BBIQA2 this value was 3.08 μM. Data on the inhibitory activity of BBIQAs from the calcium
imaging experiments and from the above-described data on the muscle-type and α7 nAChRs
obtained in radioligand experiments are shown in Table 1.
To determine possible differences between d-TC and its BBIQA1 / BBIQA2 analogs in
binding to orthosteric or allosteric sites, we performed a series of calcium imaging experiments
with Neuro2a cells expressing mouse adult α1β1εδ nAChR (Fig 3C). d-TC or its analogs at
Table 1. Inhibitory effects of the alkaloids from Matis Dart Poison and d-TC on [125I]-αBgt binding, agonist-induced calcium responses, and/or currents mediated
by A. californica AChBP, T. californica nAChR, mouse adult α1β1εδ nAChR, human α7 nAChR, and mouse 5-HT3AR.
Compound Radioligand assay
A. californica AChBP T. californica nAChR α7 nAChR
IC50, μM nH IC50, μM nH IC50, μM nH
(95% CI) (mean ± SEM) (95% CI) (mean ± SEM) (95% CI) (mean ± SEM)
d-TC 2.41 -1.05 ± 0.02 0.39 -1.28 ± 0.11 7.77 -1.02 ± 0.05
(2.26–2.56) (0.31–0.47) (6.72–8.81)
BBIQA1 3.80 -1.39 ± 0.09 26.3 -1.13 ± 0.02 162 -1.19 ± 0.10
(3.47–4.13) (24.7–27.8) (148–191)
BBIQA2 7.63 -1.16 ± 0.11 8.75 -0.69 ± 0.05 5.52 -0.82 ± 0.05
(5.28–9.97) (7.22–10.27) (4.50–6.55)
BBIQA3 − − 17.0 -1.05 ± 0.02 − −
(16.4–17.7)
Compound Calcium Imaging Electrophysiology
α1β1εδ nAChR α7 nAChR 5-HT3AR
IC50, μM nH IC50, μM nH IC50, nM nH
(95% CI) (mean ± SEM) (95% CI) (mean ± SEM) (95% CI) (mean ± SEM)
d-TC 0.81 -1.87 ± 0.41 2.03 -1.39 ± 0.21 22.63 -1.19 ± 0.21
(0.50–1.12) (1.31–2.76) (10.49–34.78)
BBIQA1 0.75 -0.96 ± 0.16 1.70 -0.83 ± 0.17 119.4 -1.06 ± 0.09
(0.28–1.21) (1.11–2.61) (74.4–164.4)
BBIQA2 1.75 -1.04 ± 0.21 3.08 -0.94 ± 0.29 1975 -1.83 ± 0.01
(0.88–2.61) (1.47–4.68) (1861–2090)
https://doi.org/10.1371/journal.pone.0210182.t001
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different concentrations (at IC50 and 3x IC50, see Table 1: Calcium Imaging for α1β1εδ
nAChR) were co-applied along with acetylcholine to Neuro2a cells expressing α1β1εδ nAChR.
As shown in Fig 3C, the presence of d-TC, BBIQA1, or BBIQA2 shifts the acetylcholine dose
response curve to the right, with an increased acetylcholine EC50 value (Table 2), and reduces
the maximal acetylcholine response (Fig 3C).
Electrophysiology
We also analyzed the interactions of d-TC, BBIQAs1 and 2 with several subtypes of hetero-
meric neuronal nAChRs, namely α3β2, α4β2, and α9α10, following their expression in X. lae-
vis oocytes. As is seen in Fig 4A and 4B, both BBIQAs and d-TC have similar inhibitory
activities against all three neuronal nAChR subtypes. We also wanted to check whether d-TC
and BBIQAs differ in their activity towards other Cys-loop receptors. Fig 4C shows that a
strong (90%) inhibition of the mouse α3β2γ2 GABAAR is observed with a high concentration
Fig 3. Dose-response curves of inhibitory activity of d-TC (open black circles), BBIQA1 (open blue triangles), and BBIQA2 (open red squares). (a) on the 30 μM
(approx. EC50) acetylcholine-evoked intracellular calcium ion concentration ([Ca
2+]i) rise in Neuro2a cells expressing mouse adult α1β1εδ nAChRs; and (b) on the
10 μM (approx. EC50) acetylcholine-evoked [Ca2+]i rise in Neuro2a cells expressing human α7 nAChRs in the presence of 10 μM PNU120596. Data are presented as
mean ± SEM, n = 3. The respective IC50 values are shown in the Table 1. (c) Dose-response curves of acetylcholine (ACh)-evoked [Ca2+]i rise in the absence (grey
circles, EC50 = 8.4 ± 0.6 μM) and presence of d-TC (black circles) or its analogs, BBIQA1 (blue triangles), and BBIQA2 (red squares) at different concentrations in
Neuro2a cells expressing mouse adult α1β1εδ nAChRs. Data are presented as mean ± SEM, n = 3. EC50 values are shown in the Table 2.
https://doi.org/10.1371/journal.pone.0210182.g003
Table 2. Inhibitory effects of the alkaloids from Matis Dart Poison and d-TC at different concentrations (IC50 and 3x IC50) on the acetylcholine dose–response
curve at mouse adult α1β1εδ nAChR expressed in Neuro2a cells.
Compound [Ca2+]i rise
α1β1εδ nAChR
ACh EC50, μM (95% CI) nH (mean ± SEM)
8.04 (5.04–11.04) 2.19 ± 0.41
Compound IC50 concentration 3x IC50 concentration
EC50, μM nH EC50, μM nH
(95% CI) (mean ± SE) (95% CI) (mean ± SE)
ACh + d-TC 33.05 3.90 ± 1.28 65.32 3.11 ± 0.78
(17.27–48.82) (41.28–89.36)
ACh + BBIQA1 26.53 0.90 ± 0.05 50.44 1.55 ± 0.34
(19.83–33.23) (23.90–76.98)
ACh + BBIQA2 17.63 1.60 ± 0.34 25.22 1.74 ± 0.14
(8.68–26.58) (21.15–29.29)
https://doi.org/10.1371/journal.pone.0210182.t002
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of d-TC (100 μM), while BBIQAs1 and 2 at this concentration produce only a 40–50%
inhibition.
As d-TC is known to potently inhibit 5-HT3AR [34, 35], we checked whether such a prop-
erty is also inherent in BBIQAs (Fig 4E). A considerable difference was detected between BBI-
QAs1 and 2: the IC50 value for the former was 119.4 nM, while for the latter was 1975 nM, and
these two compounds were 5- and 87-fold less active than d-TC, the IC50 value of which is
22.63 nM (IC50 values and 95% confidence intervals are shown in Table 1).
Fluorescence assay
For the GABAAR, we compared functional effects of the compounds on GABA-induced cur-
rents with their binding ability: Fig 4D shows that d-TC and BBIQAs 1 and 2 have similar
potency in competition assays with the fluorescent derivative of αCtx, which may bind to both
orthosteric and allosteric sites [40].
Fig 4. Activity of d-TC, BBIQAs1 and 2 against heteromeric neuronal nAChRs, GABAAR, and 5-HT3AR. (a) Representative current traces of human α3β2 nAChR,
showing inhibition of nicotine (50 μM)-induced current by 10 μM d-TC, BBIQA1, or BBIQA2. (b) Bar graph for d-TC and BBIQAs (1 and 10 μM) inhibition of
agonist-evoked currents mediated by human α3β2 (50 μM Nicotine), rat α4β2 (10 μM Nicotine), and human α9α10 (25 μM Acetylcholine) nAChRs. (c) Bar graph for
d-TC and BBIQAs (100 μM) inhibition of agonist-evoked currents mediated by mouse α3β2γ2 GABAAR (100 μM GABA). (d) Inhibition of Alexa Fluor 546 α-
cobratoxin (αCtx, 50 nM) binding to α1β3γ2 GABAAR expressed in Neuro2a cells by 50 μM d-TC, BBIQAs 1 and 2. The bar graph represents the remaining
fluorescence of Alexa Fluor 546 αCtx (50 nM). In (a, b, c, d) data are presented as mean ± SEM, n = 3–6. One-way ANOVA with Tukey’s HSD test, (black asterisks,
p<0.05, normalized current evoked by agonist in the presence of d-TC, BBIQA1, or BBIQA2 vs normalized current induced by agonist in the absence of antagonists).
(e) Dose-response curves of d-TC (open black circles), BBIQA1 (open blue triangles), or BBIQA2 (open red squares) inhibitory action on 1 μM 5-HT-evoked ion
currents mediated by mouse 5-HT3AR. Data are presented as mean ± SEM, n = 3–5. IC50 values determined from these data are shown in Table 1.
https://doi.org/10.1371/journal.pone.0210182.g004
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Discussion
In this study we compared the effects of d-TC and the structurally-related BBIQAs on the mus-
cle-type and neuronal nAChRs, as well as on 5-HT3AR and GABAAR. The data obtained sug-
gest that the BBIQAs do not completely mimic the effects of d-TC, and thus could provide
useful tools for future studies.
Computer modeling with A. californica AChBP revealed that the BBIQAs may bind to Cys-
loop receptors with high affinity at the orthosteric sites, as d-TC does. Indeed, radioligand binding
assay with A. californica AChBP showed that both BBIQA1 and BBIQA2 had the affinity almost
indistinguishable from that of d-TC. However, radioligand assays with T. californica nAChR
revealed that BBIQAs are significantly less potent than d-TC in their ability to inhibit binding of
[125I]-αBgt. It is well-established that αBgt interacts with the binding sites for agonists and com-
petitive antagonists (in other words, binds to the orthosteric sites [52, 53]), so our results suggest
that the BBIQAs are less potent than d-TC in binding to that site. In calcium imaging experiments
on the adult muscle nAChR, the IC50 values for BBIQA1 and BBIQA2 were roughly equal to
those of d-TC, in being in the micromolar range and indicating that d-TC, BBIQAs 1 and 2 can-
not be considered as highly potent drugs. However, the analysis of the relationship between the
neuromuscular blocking dose and duration of action revealed that it is reciprocal, and the rapid
onset and short duration of action are associated with drugs of low potency [26, 54, 55]. Therefore,
low potency of BBIQAs, as well as of d-TC, may be a positive characteristic in terms of their drug-
like properties, justifying further structure-functional analysis of these compounds.
Interestingly, our calcium imaging data for muscle α1β1εδ nAChR revealed the BBIQAs
potencies similar to that of d-TC, in contrast to radioligand assay data where all three BBIQAs
were much weaker than d-TC, indicating that inhibition of a functional response was more
complex than a simple competition. We assumed that these data could be explained by the
BBIQAs binding to multiple sites on the receptor: nAChRs are large multisubunit proteins
with various binding sites, orthosteric and allosteric, both in the LBD and in the transmem-
brane domain [56–58]. Indeed, it is well known that d-TC is able to target both the orthosteric
and allosteric sites [24, 59–62].
Calcium imaging is a convenient method for probing nAChR inhibition [39, 47, 63]. In
[47] the researchers used it with genetically encoded calcium ion sensor to study the mecha-
nism of nicotinic receptors (α7 and α4β2 nAChRs) inhibition by well-known competitive
antagonists (methyllycaconitine and dihydro-β-erythroidine, respectively). In the presence of
competitive antagonist, the agonist dose-response curve shifts to the right with no reduction in
the amplitude of the maximal response. Noncompetitive inhibition could as well be detected
by calcium imaging with genetically encoded calcium ion sensor Case12. It was previously
detected that baptide 2, a short peptide from puff adder Bitis arietans venom, inhibits α1β1εδ
nAChR in noncompetitive way: the pre-incubation with baptide 2 doesn’t shift the acetylcho-
line dose-response curve to the right, but reduces the maximal amplitude of the responses
[63]. Here we also checked the applicability of the calcium imaging with Case12 on the exam-
ple of α1β1εδ nAChR inhibition by a well-known competitive antagonist, αBgt. A 5 min pre-
incubation of Neuro2a cells with αBgt (100 nM) shifts the acetylcholine dose-response curve
to the right, and the agonist EC50 value increases from 11.5 μM to 44.2 μM (S8 Fig). Moreover,
we did not observe any reduction in the maximal amplitude of the cellular responses (S8 Fig).
This indicates clearly that under conditions described in this article calcium imaging is appli-
cable for the detection of competitive antagonism.
We compared BBIQA1, BBIQA2, and d-TC by this calcium imaging test and detected quite
unusual effect of all three compounds on the acetylcholine dose-response curve for the α1β1εδ
receptor: in addition to the curve shift to the right (with increasing agonist EC50 value, see
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Table 2), for all three compounds there was a concomitant reduction of peak acetylcholine
responses (Fig 3C). This finding, along with the results of radioligand assay, supports our
hypothesis that BBIQA1 and BBIQA2 inhibit adult muscle α1β1εδ nAChR by mixed mecha-
nisms, in which both competitive and noncompetitive modes are involved. For d-TC this
mixed mechanism was confirmed by the earlier data [60], where the same effect on the mus-
cle-type nAChR was observed in the electrophysiology experiments.
In GH4C1 cells expressing α7 nAChR, d-TC competitively inhibits binding as previously
reported [31]. BBIQA2 is also able to compete with [125I]-αBgt with a potency similar to d-TC,
but BBIQA1 is considerably less potent. On the contrary, in calcium imaging experiments, we
did not see any strong differences in the inhibitory potencies of all three compounds. Thus
BBIQA1 might also interact with allosteric sites in α7 nAChR. A similar example has been
reported for the muscle-type receptor [60], where the use of nondesensitizing agonist (e.g.
DMPP) resulted in competitive inhibition by d-TC, instead of noncompetitive inhibition in
the case of acetylcholine-evoked responses. Thus, the mechanism is dependent on the receptor
activation mode [60]. However, we must be cautious, as the calcium imaging experiments
were performed in the presence of positive allosteric modulator PNU120596 (see above),
which decreases the receptor desensitization.
The data for α3β2, α4β2, and α9α10 nAChRs show that against them BBIQAs and d-TC have
very similar inhibitory potencies. A comparable inhibitory activity of d-TC and BBIQAs against
α9α10 nAChR is of considerable importance because these receptors are targets for the develop-
ment of new analgesics, among which several α-conotoxins are being explored [64]. Both BBIQA1
and BBIQA2 demonstrate some decrease in their inhibiting potencies at GABAAR in comparison
with d-TC in electrophysiological experiments, but there were no significant differences between
them in competition with Alexa Fluor 546 αCtx, which can bind both to orthosteric and allosteric
sites [40]. Thus, the situation with GABAAR might also indicate a more complicated inhibitory
mechanism, in which binding to orthosteric and allosteric sites could be involved.
At 5-HT3AR, however, BBIQA1 and BBIQA2 behave quite differently, being 5- and 87-fold
less active than d-TC, thus demonstrating that compared to d-TC BBIQAs are less selective for
5-HT3AR than nAChRs. This finding may be important since some α7 nAChR targeting drugs
are problematic because they also act on 5-HT3R. Further investigating of key structural ele-
ments responsible for mechanisms of action of these compounds might be very useful for
future drug design.
Supporting information
S1 Table. Predicted affinity of the alkaloids from Matis Dart Poison and d-TC for AChBP
from A. californica.
(DOCX)
S1 Fig. Computer docking of the BBIQA1 and BBIQA2 to A. californica AChBP. Docked
structures overlay of (a) BBIQA1 (purple) and d-TC (black) revealing differences in the pre-
dicted binding modes and (b) BBIQA2 (purple) and d-TC (black) revealing similarity in the
predicted binding modes. Despite the difference in binding configurations, both BBIQA1 (c)
and BBIQA2 (d) were docked at the classic orthosteric site under the loop C of the AChBP.
(TIF)
S2 Fig. Analytical HPLC data for BBIQA1 purification.
(TIF)
S3 Fig. MS data for the BBIQA1.
(TIF)
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S4 Fig. Analytical HPLC data for BBIQA2 purification.
(TIF)
S5 Fig. MS data for the BBIQA2.
(TIF)
S6 Fig. Analytical HPLC data for BBIQA3 purification.
(TIF)
S7 Fig. MS data for the BBIQA3.
(TIF)
S8 Fig. Dose-response curves of acetylcholine (ACh)-evoked [Ca2+]i rise in the absence
(grey circles, EC50 = 11.5 ± 1.43 μM) and presence of 100 nM αBgt (violet circles, EC50 =
44.2 ± 8.38 μM) in Neuro2a cells expressing mouse adult α1β1εδ nAChRs. Data are pre-
sented as mean ± SEM, n = 3.
(TIF)
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